News | November 03, 2011

Lantheus Announces Labeling Changes for Definity Ultrasound Contrast

November 3, 2011 – Lantheus Medical Imaging announced important changes to the U.S. product label for Definity Vial for (perflutren lipid microsphere) Injectable Suspension. The contrast agent is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

 After a review of Lantheus’ 2010 application for proposed label changes submitted to the U.S. Food and Drug Administration (FDA), the following revisions have been made to the prescribing information for Definity:

·         Removal of the statement from the boxed warning: “In patients with pulmonary hypertension or unstable cardiopulmonary conditions, monitor vital sign measurements, electrocardiography and cutaneous oxygen saturation during and for at least 30 minutes after Definity administration.” Similar language was also removed from the warning section of the label.

·         Addition of the statement to the boxed warning: Most serious reactions occur within 30 minutes of administration,” which is consistent with the current information in the warning section.

·         Removal of the statement from the product indications and usage section of the label: “The safety and efficacy of Definity with exercise stress or pharmacologic stress testing have not been established.”

·         Addition of the further qualifier in the statement in the warning section: “Serious cardiopulmonary reactions, including fatalities, have occurred ‘uncommonly’ during or following perflutren-containing microsphere administration.”

·         Inclusion of summary data from post-approval CaRES (Contrast echocardiography Registry for Safety Surveillance) safety registry in the post-marketing experience section and from post-approval pulmonary hypertension study in the clinical trials experience section.

For more information: www.definityimaging.com

 

Related Content

Technology | Ultrasound Imaging | August 18, 2017
August 18, 2017 — SuperSonic Imagine recently introduced the newest version of its premium...
Pentax Medical Launches New Slim Linear Ultrasound Endoscope
Technology | Endoscopes | August 17, 2017
Pentax Medical Co. announced the U.S. launch of the Slim Linear Ultrasound Endoscope (EG-3270UK), the company's newest...
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Clarius Wireless Ultrasound Scanners Now Available With Advanced Features
News | Ultrasound Imaging | August 09, 2017
Clarius Mobile Health has released advanced features and options for its wireless handheld ultrasound scanner for...
Oregon Tech Partners with Mindray for High-Tech Ultrasound Education
News | Ultrasound Imaging | August 04, 2017
To better prepare its ultrasound students to compete and thrive in the evolving healthcare environment, Oregon...
Carestream Shows Touch Prime Systems at Society for Vascular Ultrasound Conference
News | Ultrasound Imaging | August 03, 2017
Carestream will showcase its Carestream Touch Prime and Touch Prime XE Ultrasound Systems at the Society for Vascular...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
3-D Vascular Ultrasound Quantifies Plaque Burden to Estimate Cardiovascular Risk
News | Cardiovascular Ultrasound | July 20, 2017
In a large, first-of-its-kind population, researchers found an experimental technique known as three-dimensional...
Overlay Init